APx Acquisition I said it received a notice from the Nasdaq that it was out of compliance with listing requirements for failure to file a 10-K for the period ended Dec. 31 nor a 10-Q for the period ended March 31. The SPAC has 60 days to submit a plan to regain compliance. If the Nasdaq accepts the plan, the APx would have until Sept. 27 to evidence compliance.
APx in March announced a merger agreement with OmnigenicsAI, a precision medicine company incubated by Bioceres Group, and MultiplAI Health, a UK-based AI-enabled preventive medicine company. If approved, OmnigenicsAI would become a publicly listed company.
The deal values OmnigenicsAI and MultiplAI at a combined enterprise value of approximately $340 million.
Redemptions on an extension vote last year erased approximately $111.35 million from the APx trust, leaving about $68.3 million. Read more.
